PharmEng International's wholly owned subsidiary, Keata Pharma Inc., is relocating contract manufacturing operations from its Perth, Ontario facility to their its pharmaceutical manufacturing facility in Sydney, Nova Scotia. Included in the relocation from Perth are existing pharmaceutical supply contracts, manufacturing equipment and personnel.
The 46,400-sq.-ft. Sydney facility includes offices for PharmEng's pharmaceutical consulting division, pilot laboratories for formulation development, production rooms with various capabilities such as high shear mixing, container blending and equipment for modified release technologies. The facility provides formulation development and testing services to manufacture and package products in solid and liquid dosage forms. The Sydney facility has been designed to meet all cGMP requirements, the company assures.
Keata's long-term goal is to develop capabilities in other dosage forms, such as suppositories, topicals and injectables. The facility is located on five acres in the Northside Industrial Park, a 300 acre business park in North Sydney, NS. The transition from the Perth facility to the Sydney facility was completed at the end of May.